NovaBiotics

NovaBiotics is an innovative, privately-held biotech group with a bifurcated strategy. Its advanced Pharma pipeline, featuring host-directed anti-infectives like NM001 and NM002, targets significant unmet needs in cystic fibrosis, respiratory infections, and mycobacterial diseases like TB. Concurrently, its commercial Consumer Health arm generates early revenue through Tinexyl PRO, a professional-grade nail health product, providing a non-dilutive funding stream and market validation for its platform. The company is led by founder and CEO Dr. Deborah O'Neil and maintains strategic collaborations with academic and commercial partners.

Host-directed therapy platform based on the repurposing and novel formulation of cysteamine and its derivatives. The platform leverages cysteamine's host-mediated mechanisms to exert anti-inflammatory, antimicrobial (including anti-biofilm), and antiviral effects, targeting difficult-to-treat infections and inflammatory conditions.

In Pharma, NovaBiotics competes with large pharma and biotech firms developing CFTR modulators, mucolytics, and novel anti-infectives for NTM and TB. Its host-directed approach is a key differentiator. In Consumer Health, Tinexyl PRO competes with OTC antifungal treatments and prescription therapies in the nail care market, differentiating via professional podiatrist endorsement and its anti-biofilm mechanism.